Search Results - "O'Reilly, E M"

Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion by O'Reilly, E M, Hechtman, J F

“…Although rare, NTRK gene fusions are known to be oncogenic drivers in pancreatic ductal adenocarcinoma (PDAC). We report the response of a metastatic…”
Get full text

Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity? by Sahin, I.H., Askan, G., Hu, Z.I., O’Reilly, E.M.

“…The genomic-plasticity of the immune system creates a broad immune repertoire engaged to tackle cancer cells. Promising clinical activity has been observed…”
Get full text

A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas by Lee, J K, Capanu, M, O'Reilly, E M, Ma, J, Chou, J F, Shia, J, Katz, S S, Gansukh, B, Reidy-Lagunes, D, Segal, N H, Yu, K H, Chung, K-Y, Saltz, L B, Abou-Alfa, G K

“…Background: This study evaluated the addition of sorafenib to gemcitabine and cisplatin in biliary adenocarcinoma first-line therapy. Methods: Patients with…”
Get full text

'We have to discuss it': cancer patients' advance care planning impressions following educational information about cardiopulmonary resuscitation by Epstein, A. S., Shuk, E., O'Reilly, E. M., Gary, K. A., Volandes, A. E.

“…Objective Most cancer patients desire information about care options at the end of life, including cardiopulmonary resuscitation (CPR). Communicating such care…”
Get full text

Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b–based chemoradiation: ACOSOG Trial Z05031 by Picozzi, V.J., Abrams, R.A., Decker, P.A., Traverso, W., O'Reilly, E.M., Greeno, E., Martin, R.C., Wilfong, L.S., Rothenberg, M.L., Posner, M.C., Pisters, P.W.T.

“…The American College of Surgeons Oncology Group sought to confirm the efficacy of a novel interferon-based chemoradiation regimen in a multicenter phase II…”
Get full text

A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma by Duffy, A., Kortmansky, J., Schwartz, G. K., Capanu, M., Puleio, S., Minsky, B., Saltz, L., Kelsen, D. P., O'Reilly, E. M.

“…Purpose: To determine the maximum tolerated dose (MTD) of erlotinib when administered concurrently with twice weekly gemcitabine and radiation therapy (RT) for…”
Get full text

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022 by Ducreux, M., Abou-Alfa, G.K., Bekaii-Saab, T., Berlin, J., Cervantes, A., de Baere, T., Eng, C., Galle, P., Gill, S., Gruenberger, T., Haustermans, K., Lamarca, A., Laurent-Puig, P., Llovet, J.M., Lordick, F., Macarulla, T., Mukherji, D., Muro, K., Obermannova, R., O’Connor, J.-M., O’Reilly, E.M., Osterlund, P., Philip, P., Prager, G., Ruiz-Garcia, E., Sangro, B., Seufferlein, T., Tabernero, J., Verslype, C., Wasan, H., Van Cutsem, E.

“…This article summarises expert discussion on the management of patients with hepatocellular carcinoma (HCC), which took place during the 24th World…”
Get full text

Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer by Wolpin, B.M., O'Reilly, E.M., Ko, Y.J., Blaszkowsky, L.S., Rarick, M., Rocha-Lima, C.M., Ritch, P., Chan, E., Spratlin, J., Macarulla, T., McWhirter, E., Pezet, D., Lichinitser, M., Roman, L., Hartford, A., Morrison, K., Jackson, L., Vincent, M., Reyno, L., Hidalgo, M.

“…We evaluated AGS-1C4D4, a fully human monoclonal antibody to prostate stem cell antigen (PSCA), with gemcitabine in a randomized, phase II study of metastatic…”
Get full text

Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up by Conroy, T., Pfeiffer, P., Vilgrain, V., Lamarca, A., Seufferlein, T., O’Reilly, E.M., Hackert, T., Golan, T., Prager, G., Haustermans, K., Vogel, A., Ducreux, M.

“…•The guideline covers diagnosis, staging, risk assessment, treatment, disease monitoring and follow-up.•The multidisciplinary expert author group is from…”
Get full text

Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance) by Cohen, R., Shi, Q., Meyers, J., Jin, Z., Svrcek, M., Fuchs, C., Couture, F., Kuebler, P., Ciombor, K.K., Bendell, J., De Jesus-Acosta, A., Kumar, P., Lewis, D., Tan, B., Bertagnolli, M.M., Philip, P., Blanke, C., O'Reilly, E.M., Shields, A., Meyerhardt, J.A.

“…In colon cancer, tumor deposits (TD) are considered in assigning prognosis and staging only in the absence of lymph node metastasis (i.e. stage III pN1c…”
Get full text

A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression by Li, D, Pant, S, Ryan, D.P, Laheru, D, Bahary, N, Dragovich, T, Hosein, P.J, Rolfe, L, Saif, M.W, LaValle, J, Yu, K.H, Lowery, M.A, Allen, A, O'Reilly, E.M

“…Abstract Background Nucleotide transporters such as human equilibrative nucleoside transporter-1 (hENT1) play a major role in transporting gemcitabine into…”
Get full text

Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer by Bendell, J., O'Reilly, E.M., Middleton, M.R., Chau, I., Hochster, H., Fielding, A., Burke, W., Burris, H.

“…We identified olaparib 100 mg b.i.d. (intermittent) with gemcitabine 600 mg/m2 as a tolerated dose combination, which could be considered for future…”
Get full text

Controversies in upper GI oncology: maintenance treatment in pancreatic cancer by Dekervel, J., Laheru, D., O’Reilly, E.M.

Get full text

Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC) by Duffy, A., Capanu, M., Abou-Alfa, G.K., Huitzil, D., Jarnagin, W., Fong, Y., D'Angelica, M., DeMatteo, R.P., Blumgart, L.H., O'Reilly, E.M.

“…Background The incidence of gallbladder cancer (GBC) in the US is 1.2/100,000. This report examines the patterns of presentation, adjuvant treatment and…”
Get full text

Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib by Hammel, P., Kindler, H.L., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M.J., Park, J.O., Hochhauser, D., Arnold, D., Oh, D.-Y., Reinacher-Schick, A., Tortora, G., Algül, H., O’Reilly, E.M., McGuinness, D., Cui, K.Y., Joo, S., Yoo, H.K., Patel, N., Golan, T.

“…Patients with metastatic pancreatic cancer often have a detriment in health-related quality of life (HRQoL). In the randomized, double-blind, phase III POLO…”
Get full text

A pilot study of gemcitabine, nab-paclitaxel, PEGPH20 (PAG) and rivaroxaban for advanced pancreatic adenocarcinoma: Interim safety and efficacy analysis by Yu, K., Mantha, S., Tjan, C., Kaufmann, E., Brenner, R.B., Lowery, M., Ku, G., Raj, N., Shcherba, M., Goldberg, Z., Li, J., Zervoudakis, A., Hamilton, A., Won, E., Do, R.K.G., O’Reilly, E.M.

Get full text

Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC) by Das, R K, Furchtgott, L, Ou, F-S, Swanson, D, Hayete, B, Harms, B, Cunha, D, Latourelle, J, Wuest, D, Khalil, I, Washburn, C, Rich, K, Blanke, C D, Meyerhardt, J, Niedzwiecki, D, Nixon, A, O'Reilly, E M, Innocenti, F, Lenz, H-J, Venook, A

Get full text

Genomics and pharmacogenomics of pancreatic adenocarcinoma by Lowery, M A, O'Reilly, E M

“…The last decade has brought significant advances in the development of molecularly targeted therapies for treatment of a variety of human malignancies. In…”
Get full text

Combination of human tumor necrosis factor-alpha (hTNF-α) gene delivery with gemcitabine is effective in models of pancreatic cancer by Murugesan, S R, King, C R, Osborn, R, Fairweather, W R, O'Reilly, E M, Thornton, M O, Wei, L L

“…Pancreatic adenocarcinoma is an aggressive and highly lethal malignancy. Currently, gemcitabine is commonly used in patients with pancreatic cancer. However,…”
Get full text

Pancreatic adenocarcinoma in a young patient population-12-year experience at Memorial Sloan Kettering Cancer Center by Duffy, A., Capanu, M., Allen, P., Kurtz, R., Olson, S.H., Ludwig, E., Klimstra, D.S., O'Reilly, E.M.

“…Background There is a dearth of data in a younger population of patients with pancreatic ductal adenocarcinoma (PAC) regarding epidemiology, genetics,…”
Get full text